ROME Therapeutics Funding & Investors
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
rometx.comTotal Amount Raised: $199,000,000
ROME Therapeutics Funding Rounds
Series B
$72,000,000
Series B Investors
Johnson & Johnson Innovation – JJDCAxon VenturesBristol-Myers SquibbAlexandria Venture InvestmentsAndreessen HorowitzLuma GroupSigmas GroupMirae Asset CapitalMass General Brigham VenturesSanofi VenturesSection 32GVArchVenturesCasdin CapitalSeries B
$77,000,000
Series B Investors
Mass General Brigham VenturesArch Venture PartnersSanofi VenturesSection 32GVAlexandria Venture InvestmentsCasdin CapitalAndreessen HorowitzSeries A
$50,000,000
Series A Investors
Partners Innovation FundArch Venture PartnersGV
Funding info provided by Diffbot.